 |
Top 10 CAR-T startups in USA
Oct 23, 2024 | By Jason Kwon | 24 |
1
Funding: $112M
AvenCell Therapeutics develops next generation immunotherapies for hard-to-treat cancers.
AvenCell Therapeutics develops next generation immunotherapies for hard-to-treat cancers.
2
Funding: $87.6M
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
Inceptor Bio develops cell therapy solutions to cure difficult-to-treat cancers.
3
Funding: $1.3B
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
Fate Therapeutics is a stem cell and developmental biology research company using biological mechanisms to develop stem cell therapeutics.
4
Funding: $1B
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
5
Funding: $460.5M
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
Poseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics.
6
Funding: $369.5M
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
Humanigen is a biopharmaceutical company that uses its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. It focuses on preventing the serious and potentially life-threatening side-effects associated with chimeric antigen receptor T-cell (CAR-T) therapy.
7
Funding: $340M
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
Capstan Therapeutics is advancing cell engineering to develop CAR-T therapeutics for a broad range of diseases.
8
Funding: $293.4M
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
9
Funding: $256M
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.
10
Funding: $210M
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
